Characterization of Alzheimer’s Disease and Mild Cognitive Impairment in Older Adults in Panama

Villarreal, Alcibiades; Grajales, Shantal; O’Bryant, Sid; Edwards, Melissa; López, Lineth; Montalván, Astevia; Britton, Gabrielle B.

doi:10.3233/jad-160402

Cited by 10 publications

(24 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is one of our most relevant results concerning cognitive impairment and other age-related conditions. [6] Notably, 32.6% of participants tested (n = 267) had at least one copy of APOE4. Table 2 summarizes the distribution of APOE genotypes by age group.…”

Section: Lessons Learned From Intervention Resultsmentioning

confidence: 98%

“…Among the cognitive, physical function and depression variables, participants aged ≥85 years scored lower on cognitive tests, and had more BADL and IADL limitations and depressive symptoms. [4,7] For Panama, PARI provided the fi rst data regarding health-related factors in older adults, a line of research that has been active in most high-income countries for decades. In the initial cohort, we collected information on a wide range of variables and reported age-related impairments in cognition and everyday function, many of which were expected based on the international literature.…”

Section: Lessons Learned From Intervention Resultsmentioning

confidence: 99%

“…The methodology published previously was based on standard protocols for conducting longitudinal studies of cognitive health in older adults. [4][5][6][7][8] Participants were recruited from the outpatient geriatric services of the Social Security Fund's Dr Arnulfo Arias Madrid Hospital Complex (Complejo Hospitalario Dr Arnulfo Arias Madrid de la Caja de Seguro Social, CHAAM-CSS), the largest public hospital in Panama City. Inclusion criteria were age ≥65 years and willingness to participate in baseline and followup assessments.…”

Section: Interventionmentioning

confidence: 99%

“…and instrumental activities of daily living (BADL and IADL, respectively) were evaluated through self-report as published previously. [4,7] Clinical exams measured body mass index (BMI; kg/m 2 ), handgrip strength (kg), pulse rate and blood pressure.…”

Section: Lessons From the Fieldmentioning

confidence: 99%

See 3 more Smart Citations

The Panama Aging Research Initiative Longitudinal Study

Villarreal¹,

Pérez-Lao²,

Oviedo³

et al. 2019

MEDICC Rev

View full text Add to dashboard Cite

show abstract

Section: Lessons Learned From Intervention Resultsmentioning

confidence: 98%

Section: Lessons Learned From Intervention Resultsmentioning

confidence: 99%

Section: Interventionmentioning

confidence: 99%

Section: Lessons From the Fieldmentioning

confidence: 99%

See 2 more Smart Citations

The Panama Aging Research Initiative Longitudinal Study

Villarreal¹,

Pérez-Lao²,

Oviedo³

et al. 2019

MEDICC Rev

View full text Add to dashboard Cite

show abstract

“…La prevalencia de este alelo es aproximadamente del 15% en la población general y en las personas con EA es de un 40% (Bendlin et al, 2010). En Panamá, una investigación señaló que el 57% de los sujetos con EA esporádica y 50% de los sujetos con DCL tenían una o dos copias de ApoEε4 (Villareal et al, 2016). Este hallazgo sugiere que la genotipificación de APOEε4 puede complementar el diagnóstico de la EA en Panamá.…”

Section: Biomarcadores Genéticosunclassified

Deterioro Cognitivo Leve y Enfermedad de Alzheimer: Revisión de conceptos

Usma¹

2017

IPC USMA

View full text Add to dashboard Cite

La enfermedad de Alzheimer (EA) es una enfermedad neurológica degenerativa que afecta a más de 46 millones de personas alrededor del mundo. Representa el tipo de demencia más común en los adultos mayores y cursa con una alteración grave en la memoria y en la funcionalidad de la persona. La EA impacta al individuo, a su familia y/o cuidador y a la sociedad, generando grandes cargas para los sistemas sanitarios, sociales y económicos. La detección temprana de la EA se ha vuelto el foco de estudio en el área del envejecimiento en los últimos años. Diagnosticar la EA en etapas prodrómicas, cuando hay cambios cerebrales subyacentes a EA pero aún no se ha desarrollado la demencia pudiera incidir en mejorías en la intervención y en retrasar la aparición de los síntomas demenciales. Por ende es crucial estudiar el deterioro cognitivo leve (DCL), fase que precede a EA. Delimitar sus manifestaciones, criterios diagnósticos y su relación con EA es fundamental para identificar a aquellos sujetos que tienen mayor riesgo de progresar a EA. El estudio de las alteraciones cognitivas y biomarcadores de DCL y EA es la base para realizar diagnósticos diferenciales oportunos. La evaluación neuropsicológica es fundamental para determinar perfiles cognitivos y evaluar la progresión de la enfermedad. Una memoria episódica deficiente es la primera manifestación en DCL amnésico. Si la persona progresa a EA, este déficit se vuelve más severo inhabilitando la recuperación de la información. Otras funciones como la atención, el lenguaje, las capacidades visuoespaciales, razonamiento, y la flexibilidad mental pueden también estar afectadas en DCL, deteriorándose progresivamente en EA hasta deteriorar severamente la autonomía de la persona. El estudio de los biomarcadores en líquido cefalorraquídeo (LCR), estudios con neuroimagen y biomarcadores en sangre ha permitido establecer los procesos patológicos subyacentes en DCL y EA y junto con la evaluación neuropsicológica constituyen el enfoque más eficaz para el diagnóstico precoz. Abstract Alzheimer´s Disease (AD) is a neurological degenerative condition that affects over 46 million people around the world. It is the most common cause of dementia in the elderly and is characterized by a major memory impairment affecting a person’s ability to perform everyday activities. AD impacts the person, their family/caregiver and society causing a great burden on health, social and economic systems. In recent years, early detection of AD has become the main focus in aging research. Diagnosing AD in its prodromal stage, where brain pathology is present but dementia still has not appeared, is key to improving intervention mechanisms and to delay the expression of symptoms.As a result, it is crucial to study Mild Cognitive Impairment (MCI), the symptomatic pre-dementia phase. Defining MCI´s clinical manifestations, diagnostic criteria and its relation with AD is critical to the development of methods that aid in identifying individuals who are at risk of developing dementia. The study of cognitive impairment and biomarkers allows early and differential diagnosis of AD. Neuropsychological evaluation is essential to determine different cognitive profiles and to assess the progression of MCI to AD. Impairment in episodic memory, the first neuropsychological symptom of amnestic MCI, deteriorates severely if the person develops AD, affecting long term memory. Other cognitive functions such as attention, language, visuospatial abilities, reasoning and mental flexibility can be affected in MCI and deteriorate even further in AD interfering with the person´s independence and functional integrity.Likewise, the study of biomarkers in cerebrospinal fluid (CSF), neuroimaging and blood biomarkers has permitted the identification of neuropathological signs of the disease. Together with neuropsychological assessment, biomarkers constitute the most effective diagnostic approach for early detection of AD.

show abstract

Digital phenotyping: An equal opportunity approach to reducing disparities in Alzheimer's disease and related dementia research

Britton,

Huang,

Villarreal

et al. 2023

Alz & Dem Diag Ass & Dis Mo

Self Cite

View full text Add to dashboard Cite

A rapidly aging world population is fueling a concomitant increase in Alzheimer's disease (AD) and related dementias (ADRD). Scientific inquiry, however, has largely focused on White populations in Australia, the European Union, and North America. As such, there is an incomplete understanding of AD in other populations. In this perspective, we describe research efforts and challenges of cohort studies from three regions of the world: Central America, East Africa, and East Asia. These cohorts are engaging with the Davos Alzheimer's Collaborative (DAC), a global partnership that brings together cohorts from around the world to advance understanding of AD. Each cohort is poised to leverage the widespread use of mobile devices to integrate digital phenotyping into current methodologies and mitigate the lack of representativeness in AD research of racial and ethnic minorities across the globe. In addition to methods that these three cohorts are already using, DAC has developed a digital phenotyping protocol that can collect ADRD‐related data remotely via smartphone and/or in clinic via a tablet to generate a common data elements digital dataset that can be harmonized with additional clinical and molecular data being collected at each cohort site and when combined across cohorts and made accessible can provide a global data resource that is more racially/ethnically represented of the world population.

show abstract

Characterization of Alzheimer’s Disease and Mild Cognitive Impairment in Older Adults in Panama

Cited by 10 publications

References 24 publications

The Panama Aging Research Initiative Longitudinal Study

The Panama Aging Research Initiative Longitudinal Study

Deterioro Cognitivo Leve y Enfermedad de Alzheimer: Revisión de conceptos

Digital phenotyping: An equal opportunity approach to reducing disparities in Alzheimer's disease and related dementia research

Contact Info

Product

Resources

About